During the past decade, Shizuoka General Hospital conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 7 clinical trials were completed, i.e. on average, 46.7% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 4 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Shizuoka General Hospital" #1 sponsor was "Eli Lilly and Company" with 3 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "Chugai Pharmaceutical" with 2 trials sponsored, "Haruhiko Fukuda" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Shizuoka General Hospital" #1 collaborator was "Genentech, Inc." with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Ministry of Health, Labour and Welfare, Japan" with 2 trials as a collaborator, "Abbott" with 1 trials as a collaborator and "Abbott Medical Devices" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Shizuoka General Hospital" are "Breast Cancer" (3 trials), "Breast Neoplasms" (3 trials), "Gastric Neoplasm" (2 trials), "Metastatic Breast Cancer" (2 trials) and "Plaque Psoriasis" (2 trials). Many other conditions were trialed in "Shizuoka General Hospital" in a lesser frequency.

Most popular intervention types in "Shizuoka General Hospital" are "Drug" (13 trials), "Device" (4 trials), "Biological" (3 trials), "Procedure" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Docetaxel" (3 trials), "Paclitaxel" (3 trials), "Pertuzumab" (3 trials) and "Trastuzumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Shizuoka General Hospital" are 22 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Shizuoka General Hospital". undefined are not yet recruiting, 5 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Shizuoka General Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Shizuoka General Hospital, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".

Shizuoka General Hospital has several departments that took part in Clinical trials: "Shizuoka Children's Hospital" - 12 trials